Europass Curriculum Vitae

Personal information

First name(s) / Surname(s)	**Sabina Chiaretti**
Address(es)	Dipartimento di Biotecnologie Cellulari ed Ematologia, Rome, Italy Via Benevento, 6,00161, Rome, Italy
Telephone(s)	Lab:+3906441639824, :
Medical license	47587
Fax(es)	+390685705792
E-mail	chiaretti@bce.uniroma1.it
Nationality	Italian
Gender	F

Occupational field

Medical Doctor, assistant professor

Work experience

1993-1995. Attends as a medical student the Pediatric Unit of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome (Prof F. Mandelli).

1995-1999. Works as Resident in Hematology in the Pediatric and Day-Hospital Unit of the Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome (Prof F. Mandelli). During this period, she provides assistance to children with acute leukemias, Hodgkin and non-Hodgkin lymphomas, receiving chemotherapy and bone marrow transplantation.

2000-2004. Ph.D. student in Hematological Sciences, Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome (Prof. R. Foà). During the PhD period, she worked for three years at the Dana Farber Cancer Institute, Boston, MA, Department of Adult Oncology (Prof. Jerome Ritz) where she set up the oligonucleotide array technology; applied this technology for the study of acute and chronic lymphoproliferative disorders.

From June 2004 onwards. Works at the Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome (Prof. R. Foà). She has set up facility the oligonucleotide array technology, used for the analysis of acute and chronic lymphoproliferative disorders.
From the clinical standpoint, she currently takes care of adult acute lymphoblastic leukemia (ALL) patients.

Dates	
Occupation or position held	Assistant Professor from 2008
Main activities and responsibilities	Tutor of PhD students, teacher of biology to nursery students (Sapienza University) Responsible of the genomic lab at the Sapienza University, Divison of Hematology, Dept of Cellular Biotechnologies Cellular and Hematology, Rome, Via Benevento, 6, 00161Italy
Name and address of employer	Sapienza University, Divison of Hematology, Dept of Cellular Biotechnologies Cellular and Hematology, Rome, Via Benevento, 6, 00161Italy
Sector	Hematologic Sciences

Education and training

.

Dates	**1995**: Degree in Medicine with highest honors, at "*Sapienza*" University of Rome **1999**: Specialty in Hematology with highest honors, at "*Sapienza*" University of Rome **2004**: PhD in Hematologic Sciences, at "*Sapienza*" University of Rome
Title of qualification awarded	MD. PhD
Name and type of organisation providing education and training	Sapienza University of Rome
Personal skills and competences	Good knowledge of RT and quantitative PCR methods, cell cultures, Gene expression profiling MicroRNA analysis in the same setting TP53 analysis with a Roche array She has set up amplicon sequencing methods. Good knowledge of basilar bioinformatic data analysis
Mother tongue(s)	**Italian**
Other language(s)	**English**

Self-assessment	**Understanding**		**Speaking**		**Writing**
European level (*)	Listening	Reading	Spoken interaction	Spoken production	
Language	C2	C2	C2	C2	C2
Language					

(*) Common European Framework of Reference for Languages

Additional information	Include here any other information that may be relevant, for example contact persons, references, etc.
Receiving	
Annexes	List any items attached. (see below)
Scientific Publication	Author and/or co-author of 84 indexed in peer-review publication

Scientific publications

Iacobucci I, et al. *Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients*. Leukemia;24:66-73, 2010.
Haferlach T, et al. *The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report on 3334 Cases from the International MILE Study Group*. J Clin Oncol;28:2529-37, 2010.
Yoda A, et al. *Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia*. Proc Natl Acad Sci U S A;107:252-7, 2010.
Martinelli G, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol;27:5202-7, 2009.
Tavolaro S, et al. *Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors*. Leuk Res;34:733-41, 2010.
Gorello P, et al. *Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults*. Haematologica;95:79-86, 2010.
Hornakova T, et al. *ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon*. Blood;115:3287-95, 2010.
Chiaretti S, et al. *Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia (T-ALL) with myeloid-like gene features and overexpression of miR-223.* Haematologica;95:1114-21, 2010.
Messina M, et al. *Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia.* Cancer;116:3426-37, 2010.
Gorello P, et al. *SQSTM1-NUP214: a new gene fusion in adult T-cell acute lymphoblastic leukemia.* Haematologica;95:2161-3, 2010.
Chiaretti S, et al. *Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling.* Genes Chromosomes Cancer. 2011 Jan 13, 2011;50:263-74.
Messina M, et al. *AID Expression in BCR/ABL-Positive Acute Lymphoblastic Leukemia Is Associated with a Peculiar Gene Expression Profile.* Br J Haematol. 2011;152:727-32.
Torelli GF, et al. *Functional analysis and gene expression profile of umbilical cord blood regulatory T cells.* Ann Hematol. 2011 Jul 6.
Paganin M, et al. *DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T cell acute lymphoblastic leukemia: an Italian study*. Haematologica. 2011, Aug 31. Epub
Salvatori B, et al. *Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2*. Genes Cancer. 2011;2:585-92.
Guarini A, et al. *ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.* Haematologica. 2011;97(1):47-55.
Rossi D, et al. *Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness .Blood*. 2011.
Guarini A, et al. *ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.* Haematologica. 2011, Oct 11, Epub.
Salvatori B, et al. The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. Cell Death Dis. 2012 25;3:e413.
Marinelli M, et al. *Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease.* Haematologica. 2013 Mar;98(3):371-5.
Coscia M,et al. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.Blood. 2012;120(16):3271-9.
Iacobucci I,et al. *IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia*.PLoS One. 2012;7(7):e40934.
Ricciardi MR, et al. *Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.* J Mol Med (Berl). 2012;90(10):1133-44.
Rossi D, et al. *Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia*. Blood. 2012;119(12):2854-62.
Del Giudice I, et al. *NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL*. Haematologica. 2012 Mar;97(3):437-41.
Del Giudice I, et al. *Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes*. Br J Haematol. 2012 Mar;156(5):601-11.
Bacalini MG,et al. *A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis*. Exp Hematol. 2012 Mar;40(3):197-206.
Chiaretti S, et al.*TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.*Haematologica;98(5):e59-61.
Chiaretti S,et al. *Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.* Haematologica. 2013 Nov;98(11):1702-10.
Del Giudice I, et al. *Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.* Am J Hematol. 2014 Jan;89(1):74-82.
Foà R, et al. *Management of adult patients with Philadelphia positive acute lymphoblastic leukemia.* Rinsho Ketsueki. 2013 Oct;54(10):1828-37
Mauro FR,et al; *Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.* Leuk Res. 2014;38:198-203
Atak ZK, et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 2013;9(12):e1003997.
Foà R, et al. *Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.* Am J Hematol. 2014 May;89(5):480-6.
Della Starza I, et al. Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia. Br J Haematol. 2014 May;165(3):341-8.
Messina M, et al. *Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.* Blood. 2014 Apr 10;123(15):2378-88.
Brandimarte L,et al. *DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia.* Haematologica. 2014 May;99(5):64-6.
Chiaretti S, et al. *NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.* Leuk Lymphoma. 2014 Dec;55(12):2785-92.
Chiaretti S, et al. *Genomic characterization of acute leukemias.* Med Princ Pract. 2014;23(6):487-506. doi: 10.1159/000362793.
Zampieri M, et al. *The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.* Biochim Biophys Acta. 2014 Sep;1839(9):813-25.
Nunes V, et al. *A case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem cell transplant.* Leuk Lymphoma. 2014 Nov 5:1-4.
La Starza R, et al. *Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations.* Blood. 2014 Dec 4;124(24):3577-82.
Chiaretti S, et al. *Diagnosis and subclassification of acute lymphoblastic leukemia.* Mediterr J Hematol Infect Dis. 2014;(1):e2014073.
Tavolaro S, et al. *Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.* Genes Chromosomes Cancer. 2015 Apr;54(4):222-34.
Messina M, et al. *Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes*. Oncotarget. 2016, epub
Soverini S, et al. *Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients*. Leukemia 2016, epub
Chiaretti S, et al *CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.* Leuk Res. 2016 Feb;41:36-42.
Chiaretti S, Foà R. *Management of adult Ph-positive acute lymphoblastic leukemia.* Hematology Am Soc Hematol Educ Program. 2015;2015:406-13.

Textbooks (Chapters, etc.)

Manuale di Ematologia, editori Prof. P. Corradini e Prof. R. Foà, Edizioni Minerva Medica: capitolo *I microarrays in Ematologia*, insieme al Prof. R. Foà.